Introduction
Among the classic BCR-ABL-negative myeloproliferative disorders (MPDs), primary myelofibrosis (PMF) and the clinically indistinguishable entities of post-polycythemia vera or postessential thrombocythemia myelofibrosis (post-PV/ET MF) (all previously identified as myelofibrosis with myeloid metaplasia) 1 exhibit the worst phenotype in terms of both survival and quality of life. The majority of affected patients suffer from progressive cytopenia(s), profound constitutional symptoms, thrombohemorrhagic complications, marked and symptomatic organomegaly, potentially catastrophic extramedullary hematopoiesis and premature death that occurs either during the chronic phase 2 or blast phase (PMF-BP) 3 of the disease. Myeloablative and reduced intensity conditioning allogeneic stem cell transplantation are feasible and potentially of benefit for some patients with PMF and post-PV/ET MF, 4 however broad application of these treatment modalities is limited by the typically advanced age of the patients and presence of comorbidities. 5 Medical therapy for PMF (and post-PV/ET MF) is currently suboptimal and empirically derived. 6 Most recently, lenalidomide therapy was added to the therapeutic armamentarium, especially in patients with del(5q). 7, 8 Nevertheless, current drug therapy remains suboptimal and novel therapeutic approaches are urgently needed.
Tipifarnib (Zarnestra; Johnson and Johnson Pharmaceutical Research and Development, Raritan, NJ, USA, LLC) is an orally bioavailable nonpeptidomimetic inhibitor of farnesyltransferase (FTIs), 9 the enzyme that transfers the 15-carbon farnesyl group to a cysteine near the C-terminal end of selected polypeptides. FTIs were originally synthesized and tested based on the premise that FT inhibition would inhibit the membrane targeting and function of oncogenic ras mutants. [10] [11] [12] [13] Subsequent studies, however, have demonstrated that FTIs inhibit proliferation of transformed cells in vitro and in vivo even if ras mutations are absent. 14, 15 Tipifarnib initially showed provocative activity in relapsed/ refractory acute leukemia, with responses observed in 29% of patients. 16 Dose-limiting toxicity consisted of a variety of CNS manifestations, including ataxia and confusion, at doses beyond 600 mg twice daily. Two large studies have subsequently, and recently, been published confirming the activity of tipifarnib in this exceedingly high-risk population of elderly/high-risk acute myeloid leukemia (AML) with a response rate of 23% (of 158 patients) 17 and 11% (of 252 patients), 18 respectively. The current lack of effective therapy for PMF, coupled with the intriguing clinical activity reported for tipifarnib in other myeloid disorders, led us to evaluate for the antiproliferative activity of this agent against PMF progenitors in vitro. 19 This prior study demonstrated that the median tipifarnib concentrations required to inhibit colony formation by 50% were 34 and 2.7 nM for myeloid and megakaryocytic colonies from PMF patients, respectively. These results indicated that PMF progenitors should be sensitive to clinically achievable tipifarnib concentrations, which are 380 (peak) and 120 nM (trough), upon administration of 300 mg tipifarnib twice daily. 19 Therefore, based upon this in vitro activity as well as the clinical tolerability and efficacy in other myeloid malignancies, we performed a phase II trial of tipifarnib monotherapy in symptomatic patients with either PMF or post-PV/ET MF.
Methods

Patients
Patients meeting standard diagnostic criteria for PMF 2 were enrolled in this Institutional Review Board-approved trial. Patients with a diagnosis of PMF, or post-PV/ET MF and hemoglobin o10 g/dl or symptomatic splenomegaly were eligible. All patients underwent pretreatment physical examination, baseline laboratory assessment of serum chemistries and complete blood count in addition to bone marrow examination with cytogenetic and fluorescent in situ hybridization studies (to exclude occult chronic myeloid leukemia).
Therapy
Tipifarnib was administered twice daily for 21 of 28 days/cycle with a starting dose of 300 mg. Dose reductions for toxicity were allowed, with a minimum dose defined as 100 mg twice daily. After two cycles of therapy, those patients without significant (4grade 2) toxicity and stable disease were able to have the dose of tipifarnib increased by 100 mg twice daily increments per cycle until any one of the following were observed: response, toxicity (4grade 2), a maximal dose of 600 mg twice daily or a total of six cycles given. Patients responding to tipifarnib were allowed to remain on the agent at a stable dose until either disease progression or unacceptable toxicity.
Assessment of response -clinical
Primary end points for response were improvements in anemia or hepato-splenomegaly and follow the newly established criteria by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). 20 Using these criteria, a clinical improvement (CI), which is validated only if it lasts for no fewer than 8 weeks, is defined as (1) a minimum 2-g/dl increase in hemoglobin level or becoming transfusion independent (applicable only for patients with baseline hemoglobin level of less than 10 g/dl) (2) either a minimum 50% reduction in palpable splenomegaly of a spleen that is at least 10 cm at baseline or a spleen that is palpable at more than 5 cm at baseline becomes not palpable. Secondary end points of response to be evaluated included constitutional symptoms (fatigue, night sweats, fever, bone pain). The National Cancer Institute Common Toxicity Criteria (version 3.0) were used to evaluate side effects.
Assessment of response -laboratory Intramedullary manifestations of PMF. Effects of tipifarnib on the intramedullary manifestations of PMF were assessed in the following manner. First, bone marrow aspirates and trephines obtained at registration and after completion of therapy (after either six cycles or at the time of progression/ therapy termination) were examined for cellularity, reticulin fibrosis, percentage of myeloblasts, osteosclerosis and angiogenesis. Semiquantitative grading of osteosclerosis and reticulin fibrosis was performed by light microscopy according to accepted criteria. 21 Changes in angiogenesis resulting from tipifarnib were assessed as previously described 22 in a semiquantitative fashion after bone marrow microvessels were visualized by immunohistochemical staining for the CD34 antigen. Additionally G-banded karyotypic analysis was performed concurrently with cells isolated from each marrow aspirate.
Effects of therapy on circulating myeloid progenitors. At the time of registration and again while patients were receiving tipifarnib, peripheral blood mononuclear cells (PBMCs) were isolated from 10 ml ethylenediaminetetraacetic acid anticoagulated peripheral blood by double-layer FicollHypaque density centrifugation according to the method described by English and Andersen. 23 The top (PBMC) layer was removed, washed in Dulbecco's phosphate-buffered saline and counted on a hemocytometer. PBMCs were then resuspended in Iscove's modified Dulbecco's medium (Life Technology, Rockville, MD, USA) with 20% heat-inactivated fetal bovine serum (Biosource, Walkersville, MD, USA) plated into 35-mm gridded culture dishes in Methocult methylcellulose medium (Stem Cell Technologies, Vancouver, BC, Canada), which contains all the cytokines necessary for the growth of granulocyte/erythrocyte/macrophage/monocyte colonies, granulocyte/macrophage (GM) colonies, erythroid colonies and erythroid bursts, including stem cell factor, GM colonystimulating factor, granulocyte colony-stimulating factor, erythropoietin and interleukins 3 and 6. After a 14-day incubation, colonies were counted by light microscopy at Â 25 magnification according to morphological criteria established by the manufacturer. Changes in colony numbers and subtypes were compared between samples obtained at trial initiation and after (or during therapy) with tipifarnib in 20 patients.
Effects of tipifarnib on myeloid progenitors ex vivo. Paired samples harvested before and during tipifarnib therapy from 20 patients were examined for tipifarnib sensitivity ex vivo using the methodology we have described previously. 24 Briefly, aliquots containing 600 000 PBMCs (2 Â 10 6 /ml) were placed in Methocult (StemCell Technology; Vancouver, BC, Canada) containing diluent or graded drug concentrations (0-100 nM of tipifarnib) and plated as described above. After a 14-day incubation, progenitor colony numbers and subtypes were counted by light microscopy. From plots of colony number vs drug concentration, the IC 50 (concentration that inhibits colony formation by 50%) was calculated at each clinical time point. Baseline IC 50 values for tipifarnib were correlated with patient clinical and laboratory values as well as subsequent clinical response. Subsequent IC 50 values obtained at a median of 3 months (range: 1-11) after initiating tipifarnib, which were then compared to baseline values to assess whether disease progression/or persistent clinical response corresponded to changes in tipifarnib sensitivity ex vivo.
Effects of tipifarnib therapy on quantitative JAK2
V617F levels Sample procurement. This design of this clinical trial occurred just before the discovery of the important role of the JAK2 V617F in the MPDs and in PMF. However, when available, banked cytogenetic pellets obtained concurrently at the time of trial enrollment, or if a second marrow was performed, were utilized for the extraction of DNA for quantitative JAK2 mutation analysis.
qPCR assay and analysis. Quantitative PCR amplification and detection was performed by ABI Prism 7900HT Fast Real Time System (Applied Biosystems, Foster City, CA, USA). Sequence primers and MGB probes for qPCR were as follows:
. Primers were purchased from Integrated DNA Technologies Inc. (Coralville, IA, USA), and MGB probes were purchased from Applied Biosystems (Foster City, CA, USA). The reaction mix included 12.5 ml of Taqman Â 2 Universal PCR Master Mix (Applied Biosystems, Foster City, CA, USA), 0.25 ml of each primer (20 mM), 0.5 mM of each probe (2.5 mM), 10 ml of sterile water and 2 ml of sample (25 ng/ml). Samples were plated in 96-well format in triplicate. Cycling conditions consisted of 2 min at 501C, 10 min at 951C and 40 cycles of 15 s at 951C and 1 min at 601C.
Relative expression of JAK2v617f allele burden was quantified against a cocktail of homozygous JAK2v617f DNA spiked with homozygous wild-type JAK2 DNA. Specifically, genomic DNA from the cell lines K562 (CML; homozygous for wild-type JAK2) and HEL (erythroblastic leukemia; homozygous for JAK2v617f) was extracted (QIAamp DNA Blood Midi Kit, Qiagen, Valencia, CA, USA), quantified (NanoDrop Technologies, Inc., Wilmington, DE, USA) and standards of 0, 1, 5, 10, 15, 20, 25, 50, 75, 90, 95, 99 and 100% JAK2v617f were generated (final concentration: 25 ng/ml) by mixing HEL and K562 genomic DNA. Two microliters of each standard was plated in triplicate in separate wells alongside 2 ml of each sample (also plated in triplicate) per 96-well plate. A no template control was also included with each assay.
The C T values were obtained using DRn threshold of 0.2 for both mutant and wild-type analysis. Average C T values for wildtype JAK2 and JAK2v617f were calculated and DC T (C T JAK2v617f-C T JAK2WT) determined for each standard and sample. The standard curve was generated by plotting the log of each standard (increasing % mutant burden) vs DC T by linear regression. The % mutant burdens for individual samples were determined by taking the anti-log of the result after incorporating each sample DC T into the equation generated by the standard curve (y ¼ mx þ b).
Statistical analysis
Thirty-four patients were enrolled in this two-stage phase II clinical trial to test the null hypothesis that the true response probability is 5% vs the hypothesis that the true response probability is 420%. Initial responses from the first stage (3(17); 17%) led to full accrual of the second stage. The final decision rule was that at least 5 of the first 32 eligible patients needed to experience a response in order to conclude the drug is showing evidence of promising activity. An exact 95% binomial confidence interval was used to estimate the true response rate.
In order to determine whether there is an association between response and various bone marrow features of PMF, the following analyses were conducted. Fisher's exact test was used to assess the significance of the difference between distributions of categorical data. The Wilcoxon rank-sum test or the KruskalWallis was used to assess whether continuous variables differ significantly between categories. All data were analyzed using SAS software (SAS Inc., Cary, NC, USA). Corrections were made for multiple comparisons.
Results
Patients and drug toxicity
Thirty-four patients meeting the entry criteria were enrolled in this trial. The patients exhibited demographic and symptomatic distributions typical for this disorder ( Table 1 ). The median age at the time of enrollment was 66 years (range: 55-80), and 10 of the patients (29%) were females. Among the study cohort, only six patients had evidence of having developed myelofibrosis following a preexisting MPD (post-PV and post-ET MF, respectively). At registration, 13 patients were erythrocyte transfusion dependent (38%), 31 had palpable hepatomegaly/ splenomegaly and 16 had PMF-related anemia, although no patients had significant thrombocytopenia (platelet count o100 Â 10 9 per liter) based on the exclusion criteria for the trial. Patients had active disease, with nineteen patients (56%) having an adverse PMF prognostic score (X1), 26 0-2 scale where increasing number associated with worsening prognosis. Notably, 29 (85%) patients had previously received (either from lack of efficacy or toxicity) a variety of therapeutic agents for PMF (see Table 1 ), including 15 (44%) who had progressed on hydroxyurea with splenomegaly and/or leukocytosis. The median time from initial diagnosis to study registration was 26 months (range: 1-178 months). Additional baseline clinical characteristics are summarized in Table 1 .
All 34 patients started treatment with tipifarnib at 300 mg twice daily for 21 of 28 days. Overall, 14 patients (41%) completed the planned six cycles of therapy. Reasons for early discontinuation included progressive disease (n ¼ 7), toxicity/ adverse events (n ¼ 6; myalgias ¼ 2, gastrointestinal ¼ 2, fatigue ¼ 1, rash ¼ 1), patient choice (n ¼ 3), comorbidity (n ¼ 2), death unrelated to agent (n ¼ 1) and alternate treatment (n ¼ 1). Twenty-eight patients completed the first two cycles as planned, and six were discontinued early to either progressive disease, 1 toxicity (4: fatigue, musculoskeletal pain, rash and diarrhea) or death on study.
1 Of the 28 who completed the first two cycles, 12 were dose reduced. Patients receiving a dose reduction were successfully maintained at either 200 mg twice daily (11 patients) for an average of 5.5 cycles (range: 1-19) or 100 mg twice daily (1 patient) for three cycles. In aggregate, 12 patients (35%) required dose reductions, 11 patients (32%) remained on the initial dose of the agent and 11 patients (32%) underwent dose escalation to either 400 (5), 500 (2) or 600 mg (4) of tipifarnib twice daily. Although therapy with tipifarnib was generally well tolerated, myelosuppression was a problem in some patients. Myelosuppression was acute, dose limiting and required dose reductions in four patients (12%). As indicated in Table 2 , grade 3 or 4 toxicities included anemia in three (9%)patients, leukopenia in four (12%), lymphopenia in two (6%), neutropenia in four (12%), erythrocyte transfusions in one (3%) and thrombocytopenia in two (6%). Nonhematologic toxicities (that is, adverse events at least possibly related to study medication) were manageable, with seven (21%) grade 3, but no grade 4 toxicities. These nonhematologic toxicities included rash (n ¼ 2), neuropathy (n ¼ 1), hyponatremia (n ¼ 1), diarrhea (n ¼ 1), pain, 1 fatigue 1 and febrile neutropenia 1 ( Table 2) .
Tipifarnib improves refractory organomegaly in PMF
Tipifarnib was successful in alleviating symptomatic myeloproliferation in 11 patients (33%), specifically by achieving a CI for splenomegaly (four patients), hepatomegaly (four patients) or both (three patients) according to IWG-MRT criteria. 20 Additionally, tipifarnib achieved more modest reductions in splenomegaly in 20 of 27 (74%) patients with splenomegaly at baseline (one patient had been splenectomized before enrollment), and some reduction in hepatomegaly in 8 of 19 (42%) patients with symptomatic hepatic enlargement at baseline. These decreases provided significant clinical benefit with reduction of pain and mechanical symptoms. These results are significant in that 15 of these patients (44%) had already progressed on hydroxyurea (13 who initially responded and 2 without response). Additionally, these palliative benefits appeared durable, with 11 patients receiving the agent for an average of 8.4 months (range: 2-38) with continued response.
Tipifarnib demonstrated little positive effects on PMF-associated anemia
The intrinsic myelosuppressive effects of tipifarnib made an accurate assessment of the effects of the agent on PMFassociated cytopenias difficult. According to the IWG-MRT response criteria, 20 the best response observed for cytopenias was a CI for anemia in 5 of 13 patients (partial responses), who were transfusion-dependent individuals and became transfusion independent. Among the 23 individuals who were not transfusion dependent, no RBC response was seen. Anemia responses, however, tended to be short lived, lasting for 2-11 months. The efficacy of tipifarnib on improving PMF-associated thrombocytopenia could not be assessed because patients with significant thrombocytopenia were excluded at enrollment.
Tipifarnib alleviated PMF-associated constitutional symptoms
Tipifarnib successfully aided in alleviating hypercatabolic symptoms in five patients (15%). In addition, four of five patients with PMF-associated fevers and five of nine patients with night sweats experienced resolution with tipifarnib. In contrast, no improvement was noted in PMF-associated fatigue or weight loss.
Tipifarnib effects on intramedullary manifestations of PMF
Intramedullary manifestations of disease changed little during tipifarnib therapy (Table 3) . No significant changes occurred in the bone marrow cellularity, reticulin fibrosis or osteosclerosis in this population. Except for one individual (a nonresponder) whom had a 2 grade decrease in angiogenesis, no other individual had a significant (42 grade change) in any of the evaluated marrow features. In addition, karyotype abnormalities did not improve during treatment, although no new karyotypic abnormalities developed. No appreciable changes in intramedullary angiogenesis occurred as assessed by microvessel density grading by light microscopy of marrow trephines subjected to immunohistochemistry for CD34.
Correlations of response and effects on quantitative JAK2
V617F allele burden
Although the initial trial had not planned on an analysis of JAK2 V617F (given the description of this mutation occurred during the trial), quantitative JAK2 V617F mutant allele burden was able to be performed on banked cytogenetic pellets in 26 (84%) patients. Among these latter patients 10 were wild type for the mutation (39%), while those expressing the mutation had a mean 29.2% of % mutant alleles (range: 12.3 to 480%). A second, post-tipifarnib sample was available for analysis in seven patients of which no significant decrease was seen in % mutant allele burden regardless of response. Indeed in a patient whom was a clear responder for organomegaly, in which three samples were present, the % mutant allele burden rose from 33.9 to 480% over a year of therapy.
Correlations of clinical response and ex vivo tipifarnib sensitivity
Baseline assessment of circulating colony-forming cells demonstrated marked myeloproliferation, with a median of 278 GM colonies (range: 9-1410), 332 erythroid colonies (range: ) and 704 total myeloid colonies (range: 14-3360) per 600 000 circulating PBMCs. In 20 patients, subsequent colonyforming assays were available a median of 3.1 months after initiating tipifarnib (range: 1-11.5 months). These latter samples were collected before reinitiating tipifarnib for the subsequent cycle, so no tipifarnib should have been present in the patients' serum. Treatment of these individuals led to a decrease in aberrant myeloid colony formation, with a median decrease of 45% in GM colonies (range: -95 to þ 4100%) and a median decrease of 58% in erythroid progenitors (range: -100 to þ 1371%). Indeed, total myeloid colonies were decreased with tipifarnib treatment in 13/19 patients (68%), with a median decrease of 44% (range: -91 to 2936%). A third assessment after 4-13 months on tipifarnib showed a sustained decrease in myeloid colony formation in 3 of 4 patients assayed.
Tipifarnib sensitivity was also assessed in myeloid progenitors ex vivo. Dose-response curves before initiating therapy showed a median IC 50 of 11.8 nM tipifarnib (range: 0.5-200 nM), which is slightly lower than the IC 50 of 34 nM tipifarnib (range: 7.5-74.5 nM) we previously reported in myeloid progenitors from PMF patients. 24 Although progenitors from nine patients (27%) in the current group exhibited a pretreatment IC 50 434 nM, Further analysis indicated that clinical response to tipifarnib was not significantly correlated with baseline myeloid colony growth or ex vivo tipifarnib sensitivity (IC 50 values) (Wilcoxon rank-sum test). When results of the serial ex vivo dose-response curves were examined, circulating progenitors from seven patients demonstrated decreased sensitivity to tipifarnib in vitro (a 450% increase in IC 50 range (78-5120%)), while progenitors from five displayed an increase in tipifarnib in vitro sensitivity (a 450% decrease in IC 50 range (56-89%), Figure 1 ). There was a weak association between clinical responses (responder vs nonresponder) and percent change of IC 50 , although this did not reach statistical significance (P ¼ 0.068).
Discussion
In a prospective, open label, phase II trial of tipifarnib in patients with PMF (or post-PV/ET PMF), we demonstrated a certain clinical benefit against primary disease characteristics of organomegaly and transfusion-requiring anemia. Using 21 days of every 28-day dosing schedule that has previously been studied in AML and myelodysplastic syndrome (MDS), 16, 27 we found that tipifarnib was reasonably well tolerated, with myelosuppression being the main dose-limiting toxicity. Direct consequences of the myelosuppression (that is, neutropenic fever or infection), however, were rarely encountered. This myelosuppression may have masked any subtle improvements in anemia (in transfusion-independent patients) that might otherwise have been observed. Aside from myelosuppression, tipifarnib was well tolerated in this patient population. With a maximum dose of 600 mg twice daily, the serious neurotoxicity described at higher doses in the phase I AML trial was not observed. Although 50% of patients discontinued tipifarnib before the scheduled six cycles, progression of underlying disease rather than toxicity was the main reason for these premature withdrawals. Our additional observation of patients who have taken tipifarnib for 440 cycles suggests long-term tolerability of the agent.
The sustained reductions observed for symptomatic organomegaly in the PMF patients treated with tipifarnib are clinically important. Organomegaly is a definite source of morbidity in PMF patients. As a consequence of massive splenomegaly, patients experience progressive mechanical symptoms leading to early satiety, weight loss and interference with the activities of daily living. Additionally, splenomegaly leads to pain from direct mechanical effects as well as predisposition to episodes of severe pain from splenic infarctions. Finally, splenomegaly can lead to splenic sequestration of erythrocytes, leukocytes and platelets which can exacerbate the inadequate production from the afflicted marrow.
Current options for palliating splenomegaly in PMF are limited. Hydroxyurea, the best tolerated of the nonspecific myelosuppressive agents used for this purpose, is efficacious in only about a third of PMF patients and may exacerbate underlying cytopenias. Splenectomy can provide significant palliation in PMF patients but has a perioperative risk of mortality (7-9%) which limits its applicability; and postsplenectomy patients can subsequently develop hepatomegaly and thrombocytosis. 28 The observation that tipifarnib was efficacious and tolerated by patients who had failed hydroxyurea suggests a potential role of this agent as a second-line treatment for PMF patients with symptomatic splenomegaly.
The lack of clear impact of tipifarnib on intramedullary manifestations (cellularity, angiogenesis, fibrosis or karyotypic abnormalities) of PMF, as well as the lack of any improvement in baseline anemia in transfusion-independent patients, argue against the possibility that tipifarnib has a selective activity against PMF independent of myelosuppression. This conclusion is further strengthened by the lack of ability of tipifarnib to decrease mutant JAK2 V617F allele burden, even among responders.
We have previously reported that leukemic transformation in PMF is associated with a dire prognosis (median survivals of o3 months regardless of intensity of therapy). 3 Because tipifarnib has activity in high-risk MDS 29 as well as elderly and relapsed AML, 17 ,18 a logical question is whether tipifarnib will delay leukemic transformation in PMF or act as therapy once leukemic transformation has occurred. Although one patient did transform and expire from AML after enrollment in the trial, suggesting that tipifarnib might (like all other agents) be inactively transformed PMF, the current study was neither designed with sufficient power nor length of follow-up to determine any protective effect on leukemic transformation.
In summary, tipifarnib as monotherapy for PMF is reasonably well tolerated and provides a modest benefit with respect to disease-associated organomegaly even in those who have failed other standard PMF therapies. Although the next generation of therapy for PMF will likely build on the discovery of an activating point mutation in the autoinhibitory pseudokinase domain of JAK2 (the JAK2 V617F ), [30] [31] [32] [33] it is important to emphasize that this mutation is present in the vast majority of post-PV MF patients, but only about half of PMF and post-ET MF patients. 34 Moreover, until JAK2 inhibitors are shown to be efficacious and are readily available, myelofibrosis patients will continue to require palliation for symptomatic organomegaly. The present study indicates that tipifarnib, like hydroxyurea, should be considered in this role.
